. Author manuscript; available in PMC: 2019 Nov 5.

Published in final edited form as: Biol Psychiatry. 2019 Jan 17;85(10):850–862. doi: 10.1016/j.biopsych.2018.12.022

Table 2.

Subject Sample Clinical Features

	Control-w/oELA (a) (n = 13)	Control-wELA (b) (n = 13)	MDDSui-w/oELA (c) (n = 13)	MDDSui-w/ELA (d) (n = 13)	Statistics (Post Hoc Comparison of a, b, c, d)
Variables	Mean (SD) [Min, Max]	Mean (SD) [Min, Max]	Mean (SD) [Min, Max]	Mean (SD) [Min, Max]	F_3,51	ANOVA p Value	Tukey Post Hoc Test
Age of MDD Onset, Years	–	–	35.7 (14.2) [17-59]	41.1 (18.1) [17-64]	0.531	.476
Duration of MDD, Years	–	–	6.1 (7.2) [0.3-20.00]	3.6 (4.3) [0.3-11.00]	0.780	.389
Number of MDEs in Lifetime	–	–	2.0 (1.5) [1-5]	1.2 (0.4) [1-2]	1.726	.212
GAS Score	87.7 (7.1) [76-100]	85.6 (9.1) [65-100]	39.0 (16.1) [1-55]	41.8 (25.7) [1-75]	24.573	.000	a>c, a>d, b>c, b>d: p < .001
BGAS Score	12.5 (3.6) [10-21]	13.7 (6.7) [10-30]	12.3 (2.9) [10-18]	14.2 (4.7) [10-23]	0.433	.731
SPRS Total Score	9.8 (3.2) [6.00-17.00]	9.0 (2.6) [6.00-13.00]	12.9 (2.8) [10.00-17.00]	14.8 (3.7) [10.00-21.00]	7.187	.001	a>d: p = .005 b>c: p = .031 b>d: p = .002
SPRS Axis IV Impact Score	1.8 (1.0) [1.00-4.00]	2.2 (1.0) [1.00-4.00]	4.1 (1.3) [2.00-6.00]	4.3 (1.0) [2.00-5.00]	14.108	.000	a>c, a>d: p < .001 b>c, b>d: p = .002
	n (%)	n (%)	n (%)	n (%)	χ² Test	χ² p Value
SPRS Axis IV Impact Score					29.497	.014
None-minimal (1-2)	10 (76.9)	8 (61.5)	2 (15.4)	2 (15.4)
Mild-moderate (3-4)	3 (23.1)	5 (38.5)	4 (30.8)	3 (23.1)
Severe-extreme (5-6)	0	0	7 (53.8)	8 (61.5)

ANOVA, analysis of variance; BGAS, Brown–Goodwin Aggression Scale; Control-wELA, resilient control subjects with ELA; Control-w/oELA, control subjects without ELA; ELA, early life adversity; GAS, Global Assessment Scale; MDD, major depressive disorder; MDDSui-wELA, subjects with MDD who died by suicide with ELA; MDDSui-w/oELA, subjects with MDD who died by suicide without ELA; MDE, major depressive episode; SPRS, St. Paul–Ramsey Scale.